西妥昔单抗联合FOLFIRI方案治疗大肠癌肝转移的近期疗效观察  

Short-term Response of Cetuximab Combined with FOLFIRI Regimen Chemotherapy in the Treatment for Colorectal Cancer Patients with Liver Metastases

作　　者：宿濛[1] 张睿[1] 王哲[1] 秦宝丽[1] 

机构地区：[1]辽宁省肿瘤医院,辽宁沈阳100042

出　　处：《肿瘤学杂志》2015年第6期491-495,共5页Journal of Chinese Oncology

摘　　要：[目的]评价西妥昔单抗联合化疗治疗大肠癌肝转移的近期疗效和不良反应。[方法]35例大肠癌肝转移患者采用西妥昔单抗、伊立替康、亚叶酸钙、氟尿嘧啶联合化疗,2周重复1次。4周期化疗后评价疗效及不良反应。[结果]全组35例均可评价疗效,完全缓解(CR)2例,部分缓解(PR)9例,疾病稳定(SD)18例,疾病进展(PD)6例,有效率(RR)为31.43%,疾病控制率(DCR)为82.86%;中位无进展生存时间(PFS)为15.2个月,中位总生存时间(OS)为50.9个月。不良反应主要表现为痤疮样皮疹、腹泻和血液学毒性。[结论]西妥昔单抗联合FOLFIRI方案治疗大肠癌肝转移疗效肯定,其不良反应可以耐受。[Purpose]To evaluate the short-term response and toxicity of cetuximab combined with chemotherapy in the treatment for colorectal cancer patients with liver metastases. [Methods]Thirty-five colorectal cancer patients with liver metastases were treated with cetuximab,irinotecan,leucovorin and 5-Fu,every 2 weeks as a cycle. Short-term response and toxicity were evaluated after 4 cycles of chemotherapy. [Results] Efficacy could be evaluated in all the 35 patients. Of them,2 patients were complete response（CR）;9 patients,partial response（PR）;18 patients,stable disease（SD） and 6 patients,progression disease（PD）. The response rate（RR） was 31.43% and the disease control rate（DCR） was 82.86%. Progression-free survival（PFS） was 15.2 months and overall survival（OS） was 50.9 months. The common toxicities were acne-like rash,diarrhea and hematology toxicities. [Conclusion] Cetuximab combined with FOLFIRI regimen chemotherapy have certain efficacy in the treatment for colorectal cancer with liver metastases,and the toxicities are tolerable.

关 键 词：肠肿瘤 西妥昔单抗 药物疗法 不良反应 肿瘤转移 肝肿瘤 

分 类 号：R735.3[医药卫生—肿瘤] R735.7[医药卫生—临床医学]